Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Acetazolamide for the Prevention of Post Operative CSF Leak
NCT04351061 · University of Miami · PHASE2 · withdrawn · last registry update 2021-12-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No participants were identified per inclusion/exclusion criteria” | – | Registry record, University of Miami |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-12-12Also stopped (withdrawn): West Virginia University, Sufentanil (NCT04464512)
- 2022-11-03Phase 3 first posted: Arthritis Innovation Corporation, F14 + 0.25 % Bupivacaine HCl (NCT05603832)
- 2022-06-16Results posted on the registry: Jaeb Center for Health Research, Acetazolamide (NCT03501966)
- 2022-06-16Also stopped (terminated): Jaeb Center for Health Research, Acetazolamide (NCT03501966)
- 2021-06-07Phase 3 first posted: University of Zurich, Acetazolamide + Placebo (NCT04915365)
- 2021-06-04Phase 3 first posted: University of Zurich, Acetazolamide + Placebo (NCT04913389)
- 2021-05-28Phase 3 first posted: University of Turin, Italy, a drug against CA1 (NCT04907123)
- 2021-03-30Results posted on the registry: University of Colorado, Denver, Nifedipine extended release + Methazolamide (NCT02463357)
- 2020-12-22Phase 3 first posted: Mayo Clinic, Placebo + Acetazolamide (NCT04679389)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision